Results 121 to 130 of about 1,302,625 (339)
XXXVIII. First Report on Investigations into Plague Vaccines [PDF]
, 1910 Sydney Rowland
openalex +1 more source
Nanobody‐Decorated Lipid Nanoparticles for Enhanced mRNA Delivery to Tumors In Vivo
Advanced Healthcare Materials, EarlyView.This study presents a targeted mRNA‐LNP platform engineered with anti‐PSMA nanobodies for prostate cancer therapy. Using different in vivo models, the authors demonstrate selective uptake and mRNA delivery in PSMA+ cancer cells. However, while targeting is enhanced, mRNA delivery efficacy is limited by tissue penetration, tumor necrosis, and immune ...
Pol Escudé Martinez de Castilla +16 more
wiley +1 more source
The clinical progress of mRNA vaccines and immunotherapies
Nature Biotechnology, 2022 A. Barbier +4 more
semanticscholar +1 more source
Advanced Healthcare Materials, EarlyView.In a murine model of acute lung injury, pulmonary administration of lipid nanoparticles carrying TNFα siRNA enables targeted delivery to immune cells. The study emphasises the importance of optimizing LNP distribution and delivery timing to improve therapeutic outcomes and develop emergency therapies for lung hyperinflammation.
Qinglin Wang +14 more
wiley +1 more source
Discussion on Vaccine Therapy: Its Treatment, Value, and Limitations [PDF]
, 1910 P. Watson Williams
openalex +1 more source
Progress of Immune‐Inducible Biomaterials for Post‐Ablation Cancers
Advanced Healthcare Materials, EarlyView.The presence of residual tumors after ablative therapies poses a significant challenge, generally resulting in recurrence and metastases. This review offers a concise overview of immune‐inducible biomaterials from the perspective of the cancer‐immunity cycle, and how they enhance antitumor immunity through diverse mechanisms following ablative ...
Shuangshuang Zhao +7 more
wiley +1 more source
Advanced Healthcare Materials, EarlyView.A novel dissolving microneedle platform preserves HPV virus‐like particle (VLP) immunogenicity by maintaining structural integrity, crucial for eliciting potent immune responses. Buccal administration induces robust immune response, high neutralizing antibody titers, and durable sterile protection across oral and vaginal mucosal sites.
Hyemi Kim +12 more
wiley +1 more source
Human Vaccines & Immunotherapeutics, 2017 Higher-valent pneumococcal conjugate vaccines (PCVs) were licensed from 2009 in Europe; similar worldwide clinical effectiveness was observed for PCVs in routine use.
Marta Moreira +5 more
doaj +1 more source